Canaccord Genuity Starts Hi Tech Pharmacal (HITK) at Buy; Well Positioned High-Barrier Platform with Strategic Value

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/13/2026

1. CRWV
2. SMCI
3. GAMI
4. LITE
5. SPY
6. ONON
7. CAVA
8. CSCO
9. NTHI
10. ETOR

January 5, 2012 8:18 AM EST
Get Alerts HITK Hot Sheet
Price: $43.49 --0%

Rating Summary:
    1 Buy, 2 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 5 | Down: 7 | New: 3
Join SI Premium – FREE
Canaccord Genuity initiates coverage on Hi Tech Pharmacal (NASDAQ: HITK) with a Buy. PT $45.00.

Canaccord analyst, Randall Stanicky, said, "We think HITK shares can continue to grind higher on solid growth from the company’s high-barrier core business that we think brings attractive strategic value. P&L upside relative to our and Street expectations could come from (1) a stickier fluticasone opportunity than expected, (2) earlier Gx ASACOL launch or (3) business development productivity – all three possible."

For an analyst ratings summary and ratings history on Hi Tech Pharmacal click here. For more ratings news on Hi Tech Pharmacal click here.

Shares of Hi Tech Pharmacal closed at $39.45 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

New Coverage